
Bristol-Myers Squibb (BMY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.35 | $1.24 | 8.87 % |
| Q2 | Jul 30, 2026 | $2.04 | $1.61 | 26.7 % |
| Q1 | Apr 30, 2026 | $1.58 | $1.43 | 10.5 % |
| Q4 | Feb 5, 2026 | $1.26 | $1.19 | 5.88 % |
Quarterly Revenue (Billions)
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $13.07B | $12.70B | 2.94 % |
| Q2 | Jul 30, 2026 | $12.97B | $11.70B | 10.9 % |
| Q1 | Apr 30, 2026 | $11.49B | $10.92B | 5.23 % |
| Q4 | Feb 5, 2026 | $12.50B | $12.27B | 1.93 % |
Bristol-Myers Squibb (BMY) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided earnings per share in the range of $6.35 - $6.55, compared to a consensus EPS estimate of $6.54. Bristol-Myers Squibb also guided revenue in the range of $49.75B - $50.25B for the period.
Compared to prior guidance, Bristol-Myers Squibb lowered its EPS outlook from a previous range of $6.75 - $7. On the revenue side, the company raised its revenue forecast from a prior range of $49B - $50B.
Bristol-Myers Squibb has issued 16 guidance updates between February 2, 2023 and October 29, 2026. During this period, the company raised its outlook 5 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.24 | $1.61 | $1.43 | $1.19 |
| Actual | $1.35 | $2.04 | $1.58 | $1.26 |
| Surprise | +8.87% | +26.7% | +10.5% | +5.88% |
| Revenue | ||||
| Estimate | $12.70B | $11.70B | $10.92B | $12.27B |
| Actual | $13.07B | $12.97B | $11.49B | $12.50B |
| Surprise | +2.94% | +10.9% | +5.23% | +1.93% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.51 | $1.50 | $1.72 | $1.73 |
| Revenue | ||||
| Consensus | $12.68B | $11.14B | — | — |